Anti prolactinoma

Inhibiting MAPK14 showed anti-prolactinoma effect

Background: The specific underlying pathogenesis of prolactinoma has not been clarified yet to the best of our knowledge. p38 mitogen-activated protein kinase 

Inhibiting MAPK14 showed anti-prolactinoma effect

This confirms that inhibition of MAPK14 showed anti-prolactinoma effects. Abbreviations. PRL: Prolactin; MAPK: Mitogen-activated protein kinase; DRD2: Dopamine 
s z

Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells

Anti-Prolactin (PRL) Autoantibodies Cause Asymptomatic

Anti-Prolactin (PRL) Autoantibodies Cause. Asymptomatic Hyperprolactinemia: Bioassay and. Clearance Studies of PRL-Immunoglobulin G Complex*.
jcem

Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis

Immunoglobulin G Subclasses and Prolactin (PRL) Isoforms in

1 févr. 2005 IgG subclasses in patients with anti-PRL autoantibodies were ... mic subjects (six patients with prolactinoma and three pregnant women;.
jcem

Identification of driver genes and key pathways of prolactinoma

Artesunate exerts anti-prolactinoma activity by inhibiting

14 juil. 2020 Artesunate exerts anti-prolactinoma activity by inhibiting mitochondrial metabolism and inducing apoptosis. Weiyu Zhang12
b f e e b b c

Hyperprolactinémie en pratique courante. ce n'est pas si souvent un

7 févr. 2018 on basal prolactin secretion. ... prolactinoma pituitary tumour ... Traitement par anticorps monoclonaux anti-récepteur prolactine (cancer ...
lmed endocrino n

clinical course in patients with anti-prolactin autoantibody

Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody.
eje